GenFleet Therapeutics (Shanghai) Inc.
勁方醫藥科技(上海)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2595)

VOLUNTARY ANNOUNCEMENT
GFH375, Oral KRAS G12D Inhibitor, Advances into a Phase II Study Evaluating Monotherapy and Combination Regimens with EGFR Antibody or Chemotherapy in First-line Treatment of Non-small Cell Lung Cancer

This announcement is made by GenFleet Therapeutics (Shanghai) Inc. (the "**Company**" or "**GenFleet**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that GFH375 has entered a phase II study for first-line treatment of patients with advanced, KRAS G12D-mutant non-small cell lung cancer (NSCLC). The multicenter, open-label, randomized trial features three arms including GFH375 monotherapy and two combination regimens pairing GFH375 with the EGFR antibody (cetuximab) or with chemotherapy (pemetrexed). The study will be conducted in dozens of clinical sites across China, with Guangdong Provincial People's Hospital as the leading site. GFH375/VS-7375 stands as the first KRAS G12D inhibitor that received Breakthrough Therapy Designation (BTD) in China for NSCLC and has also been granted with the U.S. FDA's Fast Track designation (FTD) for locally advanced unresectable or metastatic KRAS G12D-mutant NSCLC.

Current first-line standard of care for KRAS G12D-mutant patients follows the treatment paradigm of oncogene-negative NSCLC, yielding only modest survival benefits. Moreover, effective therapeutic options after frontline progression remain scarce. Multiple real-world studies[1] show that patients with KRAS G12D mutations experience significantly poorer outcomes under first-line chemotherapy - with or without immunotherapy - compared to KRAS wild-type or non-KRAS G12D-mutant patients. GFH375 has already entered the world's first registrational phase III study of an oral KRAS G12D inhibitor in NSCLC patients, and GFH375 demonstrated best-in-class efficacy in NSCLC patients according to publicly available data of KRAS G12D inhibitor monotherapies. Notably, the updated phase I/II GFH375 monotherapy data (abstract No.

2333) in NSCLC patients have been selected for an oral presentation at this year's World Conference on Lung Cancer (WCLC) to be held in Seoul, and the presentation will take place in the section *Beyond KRAS: Emerging Targets, Smart Therapies* on September 14.

On the combination front, preclinical data presented at this year's American Association for Cancer Research (AACR) Annual Meeting demonstrated that in KRAS G12D-mutant NSCLC models, the combination of GFH375 with cetuximab delivered markedly superior antitumor activity compared with either agent alone. Besides, GFH375 advanced into a phase Ib/II trial last year evaluating combinations with chemotherapy or cetuximab across multiple solid tumors; early data indicated a favorable safety and tolerability profile with no obvious overlapping toxicities. The data from GFH375/cetuximab combination treating RAS-mutant solid tumors have been granted eligibility for full submission of a Late-Breaking Abstract (LBA) at the European Society for Medical Oncology (ESMO) Annual Meeting in 2026.

"Driven by the monotherapy efficacy of GFH375 in NSCLC and the active progression of multiple combination studies, we are confident in moving GFH375-based lung cancer therapies from late-line to the first-line setting. Over the past two years, multiple clinical programs for GFH375 have advanced efficiently, with clinical data across various tumor types consecutively selected for LBAs or oral presentations at international academic conferences. Meanwhile, we deeply recognize the urgent need of KRAS G12D-mutant patients for innovative targeted therapies and look forward to more of our innovative therapies reaching patients." stated Yu Wang, M.D., Ph.D., Chief Medical Officer of GenFleet.

1. With reference to publications including *Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer, 2023, Experimental & Molecular Medicine; Real-World outcomes of non-small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations, 2025, Lung Cancer; The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis, 2024, Cancer Cell International*

About GFH375/VS-7375

GFH375 is an orally active, potent, highly selective small-molecule KRAS G12D (ON/OFF) inhibitor designed to bind to the protein of KRAS G12D non-covalently, blocking its interaction with downstream effector proteins and thereby disrupting the sustained activation of downstream pathways and effectively inhibiting tumor cell proliferation. Preclinical studies demonstrated dose- and duration-dependent inhibition in models bearing KRAS G12D mutation; GFH375 also demonstrated low off-target risk in kinase selectivity and safety target assays. GenFleet entered into a license and early-stage development collaboration with Verastem Oncology ("**Verastem**") to advance three novel oncology discovery programs related to RAS/MAPK pathway-driven cancers. The collaboration provides Verastem with an exclusive option to obtain a license for each of the three compounds in the collaboration after the successful completion of pre-determined

milestones in a Phase I trial. Verastem selected GFH375/VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, as its lead program from the collaboration in December 2023 and the license for GFH375 that was exercised in January 2025 is the first one from this collaboration. The licenses would give Verastem development and commercialization rights outside of China while GenFleet would retain rights inside of China.

Forward-looking Statements

Specific information in this announcement may contain or constitute forward-looking words that are not historical facts. They can be identified by using forward-looking terminology, such as “predict”, “believe”, “plan”, “forecast”, “expect”, “will”, “may”, “should” and other words of similar meanings. Based on the management’s current beliefs, plans, estimates and expectations of the Company’s operation and market trends subject to changes beyond control, the forward-looking terminology reflects the Company’s beliefs, plans, estimates and expectations of future development. Actual outcome in the future may differ significantly from forward-looking words owing to market, policy, and R&D uncertainties, among others. Subject to the above-mentioned uncertainties, the Company makes no expressed or implied guarantee as to the accuracy, completeness or feasibility of this presentation, and you are cautioned not to solely rely on such forward-looking words. Neither the company nor any of its directors, officers, employees, shareholders, agents, related parties, consultants or representatives will be liable to you or any other person for consequences resulting from using this presentation. Investors are advised to exercise due diligence with reference to the company’s official disclosures for decision-making.

GLOSSARY OF TECHNICAL TERMS

“AACR”	American Association for Cancer Research
“BTD”	Breakthrough Therapy Designation
“ESMO”	European Society for Medical Oncology
“FTD”	Fast Track Designation
“KRAS”	Kirsten RAS, a member of the RAS family of proteins
“LBA”	Late-breaking Abstract
“MAPK”	mitogen-activated protein kinase, a family of proteins involved in transmitting signals from cell surface receptors to the nucleus
“NSCLC”	non-small cell lung cancer

"RAS"	ras sarcoma, a family of proteins that are critical regulators of cellular signaling pathways; it primarily includes HRAS, KRAS, and NRAS
"WCLC"	World Conference on Lung Cancer

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market GFH375 successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
GenFleet Therapeutics (Shanghai) Inc.
Dr. Qiang LU
Chairman and Executive Director

Hong Kong, August 26, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive directors; (ii) Mr. ZHU Jingyang and Ms. TAO Sha as non-executive directors; and (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive directors